amplification. The principle of prion-like polymerization seems to be conserved in signal transduction because a fungal NOD-like pattern recognition receptor also induces conversion of a fungal prion (Cai et al., 2014) . Moreover, filamentous signaling complexes with DD modules are observed in other inflammatory cascades such as antigen receptor signaling through CARD11/BCL10/MALT1 (Qiao et al., 2013) or in the Rig-I/MAVS pathway (Hou et al., 2011) . Still, many DD-containing immune adapters, including MyD88, do not form unrestrained polymers but rather form limited oligomers with presumably reversible organization (Lin et al., 2010) . The biophysical characteristics that dictate limited oligomer versus self-propagating polymer formation remain to be defined. Of note, not all inflammasomes utilize ASC. The sensor NLRC4, for instance, can activate caspase-1 independent of ASC after Salmonella typhimurium infection. Whether such mechanisms also involve prion-like protein conversion is unclear. Finally, because aberrant inflammasome activation is deleterious to the host (Schroder and Tschopp, 2010) , it must be counterbalanced to maintain homeostasis. Classical inflammatory pathways that are controlled by protein kinases or ubiquitin ligases are negatively regulated via phosphatases and de-ubiquitinases (Ruland, 2011) . The literature indicates that selective autophagy could remove filamentous CARD11/BCL10/MALT1 signalosomes after T cell activation (Paul et al., 2012) . In the future, it will be important to define whether similar mechanisms could also disassemble activated inflammasomes.
Synonymous mutations do not alter amino acids and are generally considered nonfunctional in cancer. Supek et al. now present a compelling analysis suggesting that such silent mutations can be oncogenic by altering transcript splicing and thereby affecting protein function.
Sporadic cancer is thought to arise from a cell of origin with accumulated somatic mutations. With thousands of cancer genomes and exomes sequenced, different categories of genomic alterations, such as somatic point mutations, loss or gain of chromosome material, and structural genome rearrangements, have been identified by comparing DNA from tumor cells with that from matching normal tissues. Point mutations are classified as synonymous versus nonsynonymous based on their ability to alter the encoded amino acids and thus affect protein function. Synonymous or silent mutations are categorized as passenger events because they do not modify the protein sequence and are thus considered functionally irrelevant, although their potential involvement in tumorigenesis has been suspected (Gartner et al., 2013) . In this issue, Ben Lehner and colleagues revisit this common perception of synonymous mutations in cancer (Supek et al., 2014) . By analyzing the catalog of somatic mutations detected in 3,851 cancer exomes and more than 400 whole genomes from 19 tumor types, they observed a 1.23-to 1.3-fold enrichment of silent mutations in oncogenes, but not in tumor suppressor genes, when compared to a set of noncancer genes with matching genomic features, including GC content, mRNA expression levels across tissues, and replication timing. As a reference, the enrichment of missense mutations was 2.5-fold compared to the matching gene set. Synonymous mutations were nonrandomly distributed across the gene territory, and they preferentially targeted evolutionarily conserved sites. An enrichment of silent mutations was observed near exon boundaries, suggesting a potential effect on elements that regulate pre-mRNA transcript splicing, such as exonic splicing enhancer (ESE) and loss of silencer (ESS) motifs. Indeed, when using RNAsequencing data to evaluate transcript level variability, genes with synonymous mutations exhibited an increase in differential exon usage compared to other samples of the same tissue type (Figure 1) . Association between silent coding variants and transcript isoforms was not detected in tumor suppressor genes, except for TP53, where synonymous mutations were found to be associated with inactive splice sites.
Synonymous mutations account for 20%-40% of somatic mutations detected in cancer exomes (Imielinski et al., 2012; Lawrence et al., 2013) . Commonly assumed to be spurious passenger events, these silent mutations are used to estimate background mutation frequency for genomic analysis. Algorithms such as MutSigCV (Lawrence et al., 2013) and MuSiC (Dees et al., 2012) rely on the background mutation rate to determine the significance of gene mutations, which is the probability that mutations in a certain gene are overrepresented and driving cancer. The observations by Supek et al. implicate that the background mutation frequency in oncogenes has been overestimated, whereas the incidence of functional mutations in oncogenes has been underestimated. Selective enrichment of synonymous mutations may represent an additional mechanism for oncogene activation that, if considered, could potentially enhance the power of finding novel oncogenes from the currently available sequencing data. However, for this particular study, as the majority of inferences by Supek et al. are based on oncogenes that are also targeted by missense mutations, it seems that taking the synonymous events into consideration would most likely strengthen previous observations, as opposed to identify many novel oncogenes.
Efforts to characterize the cancer genome have led to the identification of driver genes in many cancer types. However, driver gene mutations cannot be detected in a substantial percentage of tumor samples, even in tumor types with a high mutation frequency, such as lung adenocarcinoma (Imielinski et al., 2012) . Several explanations have been proposed. For instance, we may simply have not detected all driver gene mutations. Recent saturation analysis suggested that up to 5,000 cancer-normal pairs are needed to comprehensively characterize the long distribution tail of less frequently mutated cancer drivers (Lawrence et al., 2014) . In addition, mechanisms such as epigenetic alterations may complement somatic mutations in promoting tumor growth, as is the case for the mutually exclusive pattern of aberrant DNA promoter methylation and somatic mutation of the Von Hippel-Lindau gene in clear cell renal cell carcinoma (TCGA, 2013) . Functionally relevant synonymous mutations, long ignored in cancer genomics, occur in a mutually exclusive fashion with nonsynonymous mutations in the same genes, and may provide an alternate mode of oncogene activation to help explain the cause of tumorigenesis in certain tumor samples in which nonsynonymous driver gene mutations cannot be detected.
The mechanism by which synonymous mutations are able to alter oncogene activity, modulation of the splicing machinery, may open avenues for precision medicine. The presence of a synonymous mutation in a cancer driver gene may be an indication of oncogene addiction, thereby presenting a therapeutically exploitable opportunity for treating the relevant tumors. Supek et al. found that synonymous mutations were associated with increased exon expression variability, suggesting the presence of tumor-cell-specific transcripts. Small interfering RNAs (siRNAs) can mediate target mRNA cleavage and degradation with a high specificity and hold promise for effective cancer-cell-specific gene silencing (Tabernero et al., 2013) . In particular, more than 40% of ESE-altering synonymous mutations were found to be associated with the known binding site of the proto-oncogene SRSF1 (SF2/ASF) splicing factor, and ESS-interfering synonymous mutations were found to cluster near the binding site of HNRNPH2, a splicing factor that has been implicated in drug resistance (Stark et al., 2011) . These findings suggest a potential future direction for therapeutic intervention, which is to target the splicing regulatory factors instead of individual genes (Grosso et al., 2008) .
The analysis in the present study demonstrates the power of a large collection of publicly available sequence data, predominantly empowered by multi-institutional efforts such as The Cancer Genome Atlas project (http://cancergenome.nih. gov/) and International Cancer Genome Consortium project (http://icgc.org/). For the cancer research community, this work invites a new take on synonymous mutations. More importantly, it calls for a systematic functional assessment and characterization of these mutations in order to discriminate synonymous mutations with functional consequences from those that are truly futile. The findings described here suggest that synonymous mutations should be included in both quantitative modeling of cancer gene associations and clinical utility testing.
